|
Age-Related Macular Degeneration and Cataract Clinical Trials Facts presented on Clinical Trials Search isn't designed to be a substitute for proven healthcare advice, calls or treatment by using a genuine medical doctor. We aren't mDs. Always confer with your doctor on Age-Related Macular Degeneration and Cataract conditions. Clinical Trials Search.org is a website devoted to listing clinical research studies in human subjects. Age-Related Macular Degeneration and Cataract Clinical research trials and Age-Related Macular Degeneration and Cataract healthcare trials occur in a lot of of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectivity of new does drugs. The role of the studies / undertakings is to solve specific human healthcare questions. Clinical trials are a popular way for doctors, government agencies, and private sector companies to find treatments for all kinds of conditions, including Age-Related Macular Degeneration and Cataract. Age-Related Macular Degeneration and Cataract Clinical Trials and other clinical trials allow for volunteers to access health treatment choices before they are available to the general public. Many times the test subjects get treatment for without cost, and sometimes they are compensated for their time. Occasionally there is a cost for a Age-Related Macular Degeneration and Cataract clinical trial. Test subjects typically receive the most effective healthcare possible for their Age-Related Macular Degeneration and Cataract condition. Risks are a reality, nonetheless, and could include extra or frequent dr. calls, health hazards (perhaps life-jeopardizing), and/or the treatment being ineffective. Trials are federally regulated with rigid guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > Age-Related Macular Degeneration and Cataract  Age-Related Macular Degeneration and Cataract
Age-Related Macular Degeneration and Cataract
For Condition: Cataract,Macular Degeneration
Status: No longer recruiting
Sponsor(s): National Eye Institute (NEI) ,
Synopsis: Clouding of the lens, or cataract formation, accounts for vision loss in about 45 percent of the U.S. population aged 75 to 85 years. Macular degeneration-destruction of the part of the retina responsible for central vision used in reading-is the leading cause of legal blindness in people over 60 years of age. This 10-year study on age-related macular degeneration and cataract will investigate: 1. The natural course and prognosis of these diseases; 2. The effects of vitamin and mineral supplements on their development and progression; and 3. Risk factors associated with their development. Patients with age-related macular degeneration or cataract will be evaluated for their eligibility in this study with a medical history, vision test and thorough eye examination, including photographs of the lens and back of the eye. Those accepted to the study will be randomly assigned to take one of the following 4 times a day: 1) a vitamin only; 2) a mineral only; 3) both a vitamin and a mineral; or 4) a placebo (a tablet with no active ingredient). A blood sample will be drawn at the beginning of the study and once a year until its end to measure vitamin and mineral blood levels and to study their effects on cholesterol. Participants will be asked to complete a voluntary questionnaire about their visual function and how it affects their daily lives. Some patients may be asked to participate in two interviews about 6 months apart, in which they will provide information on their food intake over a 24-hour period. This information will be used to explore possible dietary risk factors for macular degeneration and cataract. Participants may also be asked to provide a small blood sample for use in studying possible hereditary factors associated with age-related macular degeneration. This research may lead to a better understanding of why the condition develops, who is likely to be affected and to what degree, and how to improve treatment.
Details: The purpose of this ancillary study is to evaluate the feasibility of studying zinc metabolism in Age-Related Eye Disease Study (AREDS) participants. All 127 AREDS participants currently followed by the National Eye Institute Clinical Center will be approached for consent. In addition to the assessment of zinc functional status, parameters of antioxidant defense and immune function capacities will be measured in consenting participants to describe the effects of zinc supplementation on these measures in this population. Results from this pilot study will be used to evaluate the feasibility of expanding enrollment to participants from other AREDS clinical centers.
Eligibility:
Study Type: Interventional, Treatment, Safety/Efficacy
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: INCLUSION CRITERIA: To be eligible for enrollment, potential participants must meet all of the following criteria: Enrolled in AREDS Followed by the NEI Clinical Center Signed the informed consent statement for this Ancillary study. EXCLUSION CRITERIA: Demonstrated inability to comply with blood drawing procedures.
Total Enrollment: 200
Location and Contact Information:
National Eye Institute (NEI)
Bethesda, Maryland, 20892
United States
Additional Information:
Study ID Numbers: 920250; 92-EI-0250
Study Start Date: August 21, 1992
Record last reviewed: August 4, 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00001312
Other Cataract Studies:
1. Randomized Trial of Aspirin and Cataracts in U.S. Physicians
2. Magnetic Resonance Imaging to Study the Normal Eye
3. Age-Related Macular Degeneration and Cataract
4. Pilot Study: Dynamic Light Scattering Device for Studying Early Changes in Cataract
5. Long Term Follow-Up of Diabetic Retinopathy
Related Studies:
Other Cataract Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
Age-Related Macular Degeneration and Cataract
|
|
|
|
|
|
|
|
